ID   AAKG2_HUMAN             Reviewed;         569 AA.
AC   Q9UGJ0; Q53Y07; Q6NUI0; Q75MP4; Q9NUZ9; Q9UDN8; Q9ULX8;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   15-MAR-2017, entry version 158.
DE   RecName: Full=5'-AMP-activated protein kinase subunit gamma-2;
DE            Short=AMPK gamma2;
DE            Short=AMPK subunit gamma-2;
DE   AltName: Full=H91620p;
GN   Name=PRKAG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Hattori A., Seki N., Hayashi A., Kozuma S., Muramatsu M., Saito T.;
RT   "Human homolog of AMPK gamma-1 chain.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=10698692; DOI=10.1042/bj3460659;
RA   Cheung P.C.F., Salt I.P., Davies S.P., Hardie D.G., Carling D.;
RT   "Characterization of AMP-activated protein kinase gamma-subunit
RT   isoforms and their role in AMP binding.";
RL   Biochem. J. 346:659-669(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RX   PubMed=11112354; DOI=10.1006/geno.2000.6376;
RA   Lang T.M., Yu L., Qiang T., Jiang J.M., Chen Z., Xin Y.R., Liu G.Y.,
RA   Zhao S.;
RT   "Molecular cloning, genomic organization, and mapping of PRKAG2, a
RT   heart abundant gamma-2 subunit of 5'-AMP-activated protein kinase, to
RT   human chromosome 7q36.";
RL   Genomics 70:258-263(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS B AND C).
RC   TISSUE=Brain, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DOMAIN CBS, AMP-BINDING, ATP-BINDING, CHARACTERIZATION OF VARIANTS
RP   WPWS GLN-302; ARG-383 AND ASN-400, CHARACTERIZATION OF VARIANT WPWS
RP   GLY-531, AND FUNCTION.
RX   PubMed=14722619; DOI=10.1172/JCI19874;
RA   Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G.,
RA   Scullion G.A., Norman D.G., Hardie D.G.;
RT   "CBS domains form energy-sensing modules whose binding of adenosine
RT   ligands is disrupted by disease mutations.";
RL   J. Clin. Invest. 113:274-284(2004).
RN   [9]
RP   DOMAIN AMPK PSEUDOSUBSTRATE, AND MUTAGENESIS OF VAL-387.
RX   PubMed=17255938; DOI=10.1038/sj.emboj.7601542;
RA   Scott J.W., Ross F.A., Liu J.K., Hardie D.G.;
RT   "Regulation of AMP-activated protein kinase by a pseudosubstrate
RT   sequence on the gamma subunit.";
RL   EMBO J. 26:806-815(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANT WPWS GLY-531.
RX   PubMed=11748095; DOI=10.1161/hc5001.102111;
RA   Gollob M.H., Seger J.J., Gollob T.N., Tapscott T., Gonzales O.,
RA   Bachinski L., Roberts R.;
RT   "Novel PRKAG2 mutation responsible for the genetic syndrome of
RT   ventricular preexcitation and conduction system disease with childhood
RT   onset and absence of cardiac hypertrophy.";
RL   Circulation 104:3030-3033(2001).
RN   [18]
RP   VARIANTS CMH6 LEU-350 INS AND ARG-383.
RX   PubMed=11371514; DOI=10.1093/hmg/10.11.1215;
RA   Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J.,
RA   Kerr B., Salmon A., Oestman-Smith I., Watkins H.;
RT   "Mutations in the gamma(2) subunit of AMP-activated protein kinase
RT   cause familial hypertrophic cardiomyopathy: evidence for the central
RT   role of energy compromise in disease pathogenesis.";
RL   Hum. Mol. Genet. 10:1215-1220(2001).
RN   [19]
RP   VARIANT WPWS GLN-302.
RX   PubMed=11407343; DOI=10.1056/NEJM200106143442403;
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RT   "Identification of a gene responsible for familial Wolff-Parkinson-
RT   White syndrome.";
RL   N. Engl. J. Med. 344:1823-1831(2001).
RN   [20]
RP   ERRATUM.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 345:552-552(2001).
RN   [21]
RP   ERRATUM.
RA   Gollob M.H., Green M.S., Tang A.S.-L., Gollob T., Karibe A.,
RA   Al Sayegh A.H., Ahmad F., Lozado R., Shah G., Fananapazir L.,
RA   Bachinski L.L., Roberts R.;
RL   N. Engl. J. Med. 346:300-300(2002).
RN   [22]
RP   VARIANTS CMH6 GLN-302; ASN-400 AND ILE-488.
RX   PubMed=11827995; DOI=10.1172/JCI0214571;
RA   Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A.,
RA   Kanter R.J., McGarry K., Seidman J.G., Seidman C.E.;
RT   "Constitutively active AMP kinase mutations cause glycogen storage
RT   disease mimicking hypertrophic cardiomyopathy.";
RL   J. Clin. Invest. 109:357-362(2002).
RN   [23]
RP   VARIANT GSDH GLN-531, AND CHARACTERIZATION OF VARIANT GSDH GLN-531.
RX   PubMed=15877279; DOI=10.1086/430840;
RA   Burwinkel B., Scott J.W., Buehrer C., van Landeghem F.K.H., Cox G.F.,
RA   Wilson C.J., Grahame Hardie D., Kilimann M.W.;
RT   "Fatal congenital heart glycogenosis caused by a recurrent activating
RT   R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase
RT   (PRKAG2), not by phosphorylase kinase deficiency.";
RL   Am. J. Hum. Genet. 76:1034-1049(2005).
CC   -!- FUNCTION: AMP/ATP-binding subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Gamma non-catalytic subunit mediates
CC       binding to AMP, ADP and ATP, leading to activate or inhibit AMPK:
CC       AMP-binding results in allosteric activation of alpha catalytic
CC       subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and
CC       preventing dephosphorylation of catalytic subunits. ADP also
CC       stimulates phosphorylation, without stimulating already
CC       phosphorylated catalytic subunit. ATP promotes dephosphorylation
CC       of catalytic subunit, rendering the AMPK enzyme inactive.
CC       {ECO:0000269|PubMed:14722619}.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=Q9UGJ0-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q9UGJ0-2; Sequence=VSP_000261;
CC       Name=C;
CC         IsoId=Q9UGJ0-3; Sequence=VSP_015589;
CC   -!- TISSUE SPECIFICITY: Isoform B is ubiquitously expressed except in
CC       liver and thymus. The highest level is detected in heart with
CC       abundant expression in placenta and testis.
CC   -!- DOMAIN: The AMPK pseudosubstrate motif resembles the sequence
CC       around sites phosphorylated on target proteins of AMPK, except the
CC       presence of a non-phosphorylatable residue in place of Ser. In the
CC       absence of AMP this pseudosubstrate sequence may bind to the
CC       active site groove on the alpha subunit (PRKAA1 or PRKAA2),
CC       preventing phosphorylation by the upstream activating kinase
CC       STK11/LKB1.
CC   -!- DOMAIN: The 4 CBS domains mediate binding to nucleotides. Of the 4
CC       potential nucleotide-binding sites, 3 are occupied, designated as
CC       sites 1, 3, and 4 based on the CBS modules that provide the acidic
CC       residue for coordination with the 2'- and 3'-hydroxyl groups of
CC       the ribose of AMP. Of these, site 4 appears to be a structural
CC       site that retains a tightly held AMP molecule (AMP 3). The 2
CC       remaining sites, 1 and 3, can bind either AMP, ADP or ATP. Site 1
CC       (AMP, ADP or ATP 1) is the high-affinity binding site and likely
CC       accommodates AMP or ADP. Site 3 (AMP, ADP or ATP 2) is the weakest
CC       nucleotide-binding site on the gamma subunit, yet it is
CC       exquisitely sensitive to changes in nucleotide levels and this
CC       allows AMPK to respond rapidly to changes in cellular energy
CC       status. Site 3 is likely to be responsible for protection of a
CC       conserved threonine in the activation loop of the alpha catalytic
CC       subunit through conformational changes induced by binding of AMP
CC       or ADP. {ECO:0000250|UniProtKB:P80385}.
CC   -!- PTM: Phosphorylated by ULK1; leading to negatively regulate AMPK
CC       activity and suggesting the existence of a regulatory feedback
CC       loop between ULK1 and AMPK. {ECO:0000269|PubMed:21460634}.
CC   -!- DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A
CC       supernormal conduction disorder characterized by the presence of
CC       one or several accessory atrioventricular connections, which can
CC       lead to episodes of sporadic tachycardia.
CC       {ECO:0000269|PubMed:11407343, ECO:0000269|PubMed:11748095,
CC       ECO:0000269|PubMed:14722619}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6)
CC       [MIM:600858]: A hereditary heart disorder characterized by
CC       ventricular hypertrophy, which is usually asymmetric and often
CC       involves the interventricular septum. The symptoms include
CC       dyspnea, syncope, collapse, palpitations, and chest pain. They can
CC       be readily provoked by exercise. The disorder has inter- and
CC       intrafamilial variability ranging from benign to malignant forms
CC       with high risk of cardiac failure and sudden cardiac death. CMH6
CC       patients present Wolff-Parkinson-White ventricular preexcitation,
CC       enlarged myocytes without myofiber disarray, and glycogen-
CC       containing cytosolic vacuoles within cardiomyocytes.
CC       {ECO:0000269|PubMed:11371514, ECO:0000269|PubMed:11827995}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Glycogen storage disease of heart lethal congenital
CC       (GSDH) [MIM:261740]: Rare disease which leads to death within a
CC       few weeks to a few months after birth, through heart failure and
CC       respiratory compromise. {ECO:0000269|PubMed:15877279}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the 5'-AMP-activated protein kinase gamma
CC       subunit family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH20540.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAS02032.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA84695.1; Type=Frameshift; Positions=228, 233; Note=Frameshifts are upstream of the initiating Met of isoform B.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB025580; BAA84695.1; ALT_FRAME; mRNA.
DR   EMBL; AJ249976; CAB65116.1; -; mRNA.
DR   EMBL; AF087875; AAK00413.1; -; mRNA.
DR   EMBL; AK001887; BAA91962.1; -; mRNA.
DR   EMBL; BT007127; AAP35791.1; -; mRNA.
DR   EMBL; AC006358; AAS02032.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC006966; AAF03528.2; -; Genomic_DNA.
DR   EMBL; AC093583; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020540; AAH20540.2; ALT_INIT; mRNA.
DR   EMBL; BC068598; AAH68598.1; -; mRNA.
DR   CCDS; CCDS43683.1; -. [Q9UGJ0-3]
DR   CCDS; CCDS47752.1; -. [Q9UGJ0-2]
DR   CCDS; CCDS5928.1; -. [Q9UGJ0-1]
DR   RefSeq; NP_001035723.1; NM_001040633.1. [Q9UGJ0-3]
DR   RefSeq; NP_001291456.1; NM_001304527.1.
DR   RefSeq; NP_001291460.1; NM_001304531.1. [Q9UGJ0-2]
DR   RefSeq; NP_057287.2; NM_016203.3. [Q9UGJ0-1]
DR   RefSeq; NP_077747.1; NM_024429.1. [Q9UGJ0-2]
DR   RefSeq; XP_016867759.1; XM_017012270.1. [Q9UGJ0-3]
DR   UniGene; Hs.647072; -.
DR   ProteinModelPortal; Q9UGJ0; -.
DR   SMR; Q9UGJ0; -.
DR   BioGrid; 119531; 24.
DR   IntAct; Q9UGJ0; 15.
DR   MINT; MINT-4831646; -.
DR   STRING; 9606.ENSP00000287878; -.
DR   ChEMBL; CHEMBL3038451; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   iPTMnet; Q9UGJ0; -.
DR   PhosphoSitePlus; Q9UGJ0; -.
DR   BioMuta; PRKAG2; -.
DR   DMDM; 14285344; -.
DR   PaxDb; Q9UGJ0; -.
DR   PeptideAtlas; Q9UGJ0; -.
DR   PRIDE; Q9UGJ0; -.
DR   DNASU; 51422; -.
DR   Ensembl; ENST00000287878; ENSP00000287878; ENSG00000106617. [Q9UGJ0-1]
DR   Ensembl; ENST00000392801; ENSP00000376549; ENSG00000106617. [Q9UGJ0-3]
DR   Ensembl; ENST00000418337; ENSP00000387386; ENSG00000106617. [Q9UGJ0-2]
DR   GeneID; 51422; -.
DR   KEGG; hsa:51422; -.
DR   UCSC; uc003wki.4; human. [Q9UGJ0-1]
DR   CTD; 51422; -.
DR   DisGeNET; 51422; -.
DR   GeneCards; PRKAG2; -.
DR   GeneReviews; PRKAG2; -.
DR   HGNC; HGNC:9386; PRKAG2.
DR   HPA; CAB018641; -.
DR   HPA; HPA004246; -.
DR   MalaCards; PRKAG2; -.
DR   MIM; 194200; phenotype.
DR   MIM; 261740; phenotype.
DR   MIM; 600858; phenotype.
DR   MIM; 602743; gene.
DR   neXtProt; NX_Q9UGJ0; -.
DR   OpenTargets; ENSG00000106617; -.
DR   Orphanet; 155; Familial isolated hypertrophic cardiomyopathy.
DR   Orphanet; 907; Wolff-Parkinson-White syndrome.
DR   PharmGKB; PA33752; -.
DR   eggNOG; KOG1764; Eukaryota.
DR   eggNOG; COG0517; LUCA.
DR   GeneTree; ENSGT00390000009849; -.
DR   HOVERGEN; HBG050431; -.
DR   KO; K07200; -.
DR   OMA; XVQIYEL; -.
DR   OrthoDB; EOG091G0CZV; -.
DR   PhylomeDB; Q9UGJ0; -.
DR   TreeFam; TF313247; -.
DR   Reactome; R-HSA-1445148; Translocation of GLUT4 to the plasma membrane.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity.
DR   Reactome; R-HSA-200425; Import of palmitoyl-CoA into the mitochondrial matrix.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q9UGJ0; -.
DR   SIGNOR; Q9UGJ0; -.
DR   ChiTaRS; PRKAG2; human.
DR   GeneWiki; PRKAG2; -.
DR   GenomeRNAi; 51422; -.
DR   PRO; PR:Q9UGJ0; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106617; -.
DR   CleanEx; HS_PRKAG2; -.
DR   ExpressionAtlas; Q9UGJ0; baseline and differential.
DR   Genevisible; Q9UGJ0; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0043531; F:ADP binding; IDA:BHF-UCL.
DR   GO; GO:0016208; F:AMP binding; IEA:Ensembl.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0008607; F:phosphorylase kinase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:BHF-UCL.
DR   GO; GO:0006754; P:ATP biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0005977; P:glycogen metabolic process; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0019217; P:regulation of fatty acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0046320; P:regulation of fatty acid oxidation; TAS:BHF-UCL.
DR   GO; GO:0046324; P:regulation of glucose import; TAS:BHF-UCL.
DR   GO; GO:0006110; P:regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0016126; P:sterol biosynthetic process; TAS:BHF-UCL.
DR   InterPro; IPR000644; CBS_dom.
DR   Pfam; PF00571; CBS; 3.
DR   SMART; SM00116; CBS; 4.
DR   PROSITE; PS51371; CBS; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cardiomyopathy; CBS domain;
KW   Complete proteome; Disease mutation; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Glycogen storage disease; Lipid biosynthesis;
KW   Lipid metabolism; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat.
FT   CHAIN         1    569       5'-AMP-activated protein kinase subunit
FT                                gamma-2.
FT                                /FTId=PRO_0000204381.
FT   DOMAIN      275    335       CBS 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00703}.
FT   DOMAIN      357    415       CBS 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00703}.
FT   DOMAIN      430    492       CBS 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00703}.
FT   DOMAIN      504    562       CBS 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00703}.
FT   NP_BIND     319    322       AMP, ADP or ATP 1.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   NP_BIND     383    384       AMP, ADP or ATP 1.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   NP_BIND     458    459       AMP 3. {ECO:0000250|UniProtKB:P80385}.
FT   NP_BIND     474    477       AMP, ADP or ATP 2.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   NP_BIND     530    531       AMP, ADP or ATP 2.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   NP_BIND     546    549       AMP 3. {ECO:0000250|UniProtKB:P80385}.
FT   MOTIF       370    391       AMPK pseudosubstrate.
FT   BINDING     302    302       AMP, ADP or ATP 2.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     362    362       AMP, ADP or ATP 1; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     383    383       AMP 3. {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     402    402       AMP, ADP or ATP 2.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     432    432       AMP 3. {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     437    437       AMP 3; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     501    501       AMP, ADP or ATP 2.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     509    509       AMP, ADP or ATP 2; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P80385}.
FT   BINDING     530    530       AMP 3. {ECO:0000250|UniProtKB:P80385}.
FT   MOD_RES      65     65       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES      71     71       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      73     73       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES      90     90       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     138    138       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     143    143       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     161    161       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     165    165       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   MOD_RES     196    196       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91WG5}.
FT   VAR_SEQ       1    241       Missing (in isoform B).
FT                                {ECO:0000303|PubMed:11112354,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.1, ECO:0000303|Ref.5}.
FT                                /FTId=VSP_000261.
FT   VAR_SEQ       1     44       Missing (in isoform C).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015589.
FT   VARIANT       6      6       M -> L (in dbSNP:rs3207363).
FT                                /FTId=VAR_048250.
FT   VARIANT     302    302       R -> Q (in WPWS and CMH6; impaired AMP-
FT                                and ATP-binding; dbSNP:rs121908987).
FT                                {ECO:0000269|PubMed:11407343,
FT                                ECO:0000269|PubMed:11827995,
FT                                ECO:0000269|PubMed:14722619}.
FT                                /FTId=VAR_013264.
FT   VARIANT     350    350       R -> RL (in CMH6; severe).
FT                                {ECO:0000269|PubMed:11371514}.
FT                                /FTId=VAR_013265.
FT   VARIANT     383    383       H -> R (in CMH6; severe; impaired AMP-
FT                                and ATP-binding; dbSNP:rs121908988).
FT                                {ECO:0000269|PubMed:11371514,
FT                                ECO:0000269|PubMed:14722619}.
FT                                /FTId=VAR_013266.
FT   VARIANT     400    400       T -> N (in CMH6; severe; impaired AMP-
FT                                and ATP-binding; dbSNP:rs28938173).
FT                                {ECO:0000269|PubMed:11827995,
FT                                ECO:0000269|PubMed:14722619}.
FT                                /FTId=VAR_013267.
FT   VARIANT     488    488       N -> I (in CMH6; severe;
FT                                dbSNP:rs121908989).
FT                                {ECO:0000269|PubMed:11827995}.
FT                                /FTId=VAR_013268.
FT   VARIANT     531    531       R -> G (in WPWS; absence of cardiac
FT                                hypertrophy; onset in childhood; impaired
FT                                AMP- and ATP-binding; dbSNP:rs121908990).
FT                                {ECO:0000269|PubMed:11748095,
FT                                ECO:0000269|PubMed:14722619}.
FT                                /FTId=VAR_032909.
FT   VARIANT     531    531       R -> Q (in GSDH; reduction of binding
FT                                affinities for AMP and ATP; loss of
FT                                cooperative binding; enhanced basal
FT                                activity; increased phosphorylation of
FT                                the alpha-subunit; dbSNP:rs121908991).
FT                                {ECO:0000269|PubMed:15877279}.
FT                                /FTId=VAR_013269.
FT   MUTAGEN     387    387       V->S: Induces phosphorylation by AMPK.
FT                                {ECO:0000269|PubMed:17255938}.
SQ   SEQUENCE   569 AA;  63066 MW;  F51C30668C294089 CRC64;
     MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS
     RKVDSPFGPG SPSKGFFSRG PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR
     MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS SSPSTPTQVT KQHTFPLESY
     KHEPERLENR IYASSSPPDT GQRFCPSSFQ SPTRPPLASP THYAPSKAAA LAAALGPAEA
     GMLEKLEFED EAVEDSESGV YMRFMRSHKC YDIVPTSSKL VVFDTTLQVK KAFFALVANG
     VRAAPLWESK KQSFVGMLTI TDFINILHRY YKSPMVQIYE LEEHKIETWR ELYLQETFKP
     LVNISPDASL FDAVYSLIKN KIHRLPVIDP ISGNALYILT HKRILKFLQL FMSDMPKPAF
     MKQNLDELGI GTYHNIAFIH PDTPIIKALN IFVERRISAL PVVDESGKVV DIYSKFDVIN
     LAAEKTYNNL DITVTQALQH RSQYFEGVVK CNKLEILETI VDRIVRAEVH RLVVVNEADS
     IVGIISLSDI LQALILTPAG AKQKETETE
//
